Medically reviewed by Mark Strehlow, MD, Medical Director — November 2026
“Wolverine stack” is a marketing name, not a molecule or a product with a fixed formula: it means two synthetic peptides, BPC-157 and TB-500, used together, in one vial or as two products, and it is promoted for faster recovery from tendon, ligament and muscle injuries. The only experiment to compare the pair with each peptide alone, an animal study in rats with a repaired Achilles tendon (2026), found the two together no better than either one. In people, no randomized or blinded trial has tested the pair; three small published reports cover twelve patients, only three of whom were given TB-500 itself, in a mouth injection with three other drugs (the other two reports name thymosin beta-4, its parent protein and a different molecule).
This review covers what is sold under the name, its FDA status and the research on the two together. Each ingredient has its own review (BPC-157, TB-500) in our peptide library. Our providers prescribe some of the peptides reviewed in this library, and we earn money from that care.
At a glance
- FDA status
- Not FDA-approved. A compounded injection combining the two is outside both the FDA’s and HHS’s compounding policies.
- Evidence in people
- No randomized or blinded trial. Three small reports, 12 patients; only three were given TB-500 itself.
- The claim you’ve heard
- Faster healing, better together: no randomized trial in people; in rats the pair beat neither peptide alone.
- Doses tested in people
- No published study has given BPC-157 with TB-500 under the skin or into muscle. No dose-finding study exists.
- Sport
- Both are prohibited at all times on WADA’s 2026 and 2027 Lists: BPC-157 (S0) and TB-500 (S2.3).
What the Wolverine stack is
“Wolverine stack” is a community and marketing name for using BPC-157 and TB-500 together. It has no official drug name and no fixed composition: a pharmacy chain’s guide calls it “a marketplace pairing, not a standardized product”. Some sources use “Wolverine” for BPC-157 alone.
The two ingredients. BPC-157 is a synthetic peptide 15 amino acids long and is not an approved drug in any country. TB-500, as the FDA and HHS define it, is a seven-amino-acid fragment of thymosin beta-4 with an acetyl group added; thymosin beta-4 itself is a protein of 43 amino acids. Sellers use the two names interchangeably, and the FDA answers that “thymosin beta-4 and TB-500 are not the same substance”. This review says which one each study used.
What is sold. Mixed injectable vials, holding equal labelled amounts of the two wherever the split is stated; two separate products on different schedules; and, on websites the FDA read, nasal sprays and capsules that combine them.
Where it stands with the FDA
Status checked: November 19, 2026.
In plain words: a compounded injection that combines BPC-157 and TB-500 is not an FDA-approved medicine, and it falls outside two federal policies under which agencies say they do not intend to act against some compounding. One is the FDA’s own; the other is a draft policy from HHS, the federal department the FDA belongs to, which names each peptide only as a single-ingredient product.
As of November 19, 2026, compounded injections that combine two or more of these peptides are not FDA-approved, and they fall outside HHS’s draft interim policy of October 30, 2026, which applies only when “the compounded drug product contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A.” They are outside the FDA’s own Category 1 policy as well. The FDA’s guidance says a drug compounded from a substance outside section 503A’s three conditions “is not eligible for the exemptions in section 503A and may violate the FD&C Act.”
Compounding means that a pharmacist or physician makes a medicine for one patient on a prescription. Section 503A is the part of federal drug law (the FD&C Act) that sets its conditions, and neither peptide meets any of the three it sets for an ingredient.
HHS’s draft policy
HHS’s draft interim policy lists six peptides, BPC-157 and TB-500 among them, and applies only “when all of the following circumstances are present”. Its stated reason for the single-ingredient condition: “It will be easier to attribute adverse events or clinical outcomes to a specific substance”. The policy says when HHS does not intend to act; it prohibits nothing, and HHS’s notice says it “is not binding on HHS or the public”.
In announcing the policy, HHS said it “does not intend to take enforcement action” against a state-licensed pharmacy or licensed physician that compounds single-ingredient BPC-157 acetate or single-ingredient TB-500 acetate, in the dosage forms the policy names for each, for a patient-specific prescription when its conditions are met. That is not FDA approval: the FDA’s own staff proposed that each “NOT be included” on its list of ingredients for compounding, though HHS says the advisory committee voted in favor; the FDA has published no minutes. State pharmacy rules apply separately.
Vials labelled “thymosin beta-4”
Some mixed vials, including the two that were recalled, are labelled “Thymosin Beta-4”, not TB-500. In a warning letter of January 20, 2026 to an outsourcing facility (a registered compounder), the FDA wrote that products “such as Thymosin Beta-4 are unapproved new drugs” and “also biological products”, and that biological products subject to licensure “are not eligible for the exemptions for compounded drugs under sections 503A and 503B of the FDCA”. The letter names neither BPC-157 nor the mixed vial, and no FDA record we read says which molecule those vials held.
Sport
Both ingredients are prohibited at all times on WADA’s 2026 and 2027 Lists: BPC-157 is named in S0 (non-approved substances), and S2.3 lists “Thymosin-ß4 and its derivatives e.g. TB-500”.
Claims you’ll see, and why sources disagree
- Two molecules share one name. Pages write “TB-500 (Thymosin Beta-4)” and borrow the protein’s research for the fragment.
- Evidence on each ingredient is counted as evidence on the pair. A clinic’s guide that promotes the stack admits it: “this complementary model is a mechanistic hypothesis extrapolated from separate animal and cell studies, not a proven clinical synergy demonstrated in humans”.
- Some pages err the other way. A consumer health page says the stack “hasn’t been tested in humans” and that its peptides are “currently not regulated in the United States”. Small human reports exist, and the FDA treats such products as unapproved new drugs.
“Not tested in people” is not the same as “doesn’t work”. It means nobody knows, and it cuts both ways: the pair has not been shown to help people, or to be safe for them.
| Claim | Level of evidence | Verdict |
|---|---|---|
| The two work better together | Animal studies (one rat study); theory | Not supported by the one test: the pair “did not confer additional benefits compared to either agent alone”. Never compared with one peptide alone in people. |
| Speeds healing of tendon, ligament and muscle injuries | Animal studies; reported in people | No randomized trial in people. In rats the pair did better than no treatment on one of three measures. |
| Reduces inflammation; builds muscle | Not tested for the pair | No study of the pair measured inflammation against a comparison, and none measured muscle. |
| “Safe” | Reported in people | Not established. No serious adverse event among the twelve patients (nine had thymosin beta-4, not TB-500); one FDA-described reaction to a mixed product; no toxicology study of the pair. |
| There is a standard dose or “protocol” | Not tested | No amount in circulation was tested in a human study, and the patterns contradict one another. |
| TB-500 is thymosin beta-4 | Contradicted | A seven-amino-acid fragment is not the 43-amino-acid protein. |
What the evidence consists of
Only studies of the two together are evidence about the stack; each ingredient’s own record is in its review.
Tested in people
No randomized, blinded or placebo-controlled study has given BPC-157 with TB-500 or with thymosin beta-4 (PubMed, Europe PMC and trial registries, November 19, 2026). One study had a comparison group, and by its paper’s description it gave thymosin beta-4, not TB-500.
Majumdar and colleagues (2026) ran an open-label pilot, not randomized and not blinded, at one centre in Cuba in ten adults with a thoracic (chest-level) spinal cord injury. Five had weekly injections under the skin of BPC-157 and of thymosin beta-4, given separately, for 26 weeks on top of rehabilitation; five had rehabilitation alone, with no placebo. At six months the leg-strength score was “29.4 ± 3.8 points” against “19.0 ± 3.5 points” (“exact two-sided p = 0.008”). The authors write that recovery in both groups “markedly exceeds published natural-history and locomotor-training benchmarks, so these results must be treated as hypothesis-generating only.”
Our check found more to doubt: its stated registration (RPCEC00000567) was not in Cuba’s trial registry on November 19, 2026; its funding line still reads “Funding: To be declared.”, while its acknowledgment thanks a company for providing the peptides; its abstract reports injection-site redness in six participants, although only five were injected and its own table lists three; and how its journal, which has no record in PubMed, reviewed the paper could not be confirmed. With five treated patients, no placebo and no group given one peptide alone, the study cannot show that the peptides caused the difference, or that the pair adds anything to either.
Reported in people
| Report | People | What was given | What happened | Limits |
|---|---|---|---|---|
| Lee and Padgett, 2021: chart review at one clinic | 16 adults with knee pain; 4 had both peptides | BPC-157 and “thymosin-beta-4 (TB4)” into the knee. The abstract never says TB-500, or what the product contained. | 3 of 4 improved; with BPC-157 alone, 11 of 12 | No comparison group; ratings recalled 6 to 12 months later; no measuring tool used |
| Froum and colleagues, 2026: three case reports | 3 adults with a nerve injury after dental surgery | BPC-157 and TB-500 in one weekly injection under the lining of the mouth, with three other drugs, for 4 weeks | Near-complete return of sensation in all three | Five agents at once. The authors: “causality cannot be established”. |
So BPC-157 has been given with TB-500, or with a product called thymosin beta-4, to twelve patients in three published reports, and only the three dental patients had a product named TB-500. None was randomized or blinded or had a group given one peptide alone, so none can show that the pair works or does more than one ingredient.
In a 2026 preprint (not peer-reviewed) of Reddit posts, 3,281 of 5,588 users (58.7%) describing use for a musculoskeletal injury reported both peptides. Of all 4,832 users who stated an outcome, “79.3% reported improvement” (users of both are not reported separately); the authors say this “cannot be taken as evidence that the peptides worked”.
Animal studies
One animal study has given the two together (Biçer and colleagues, 2026). Thirty-two rats had an Achilles tendon cut and repaired, then daily injections into the abdomen for 30 days of an inactive solution, BPC-157 (10 µg/kg), TB-500 (60 µg/kg) or both (four tendons per group for each outcome). The median load at which the tendon failed was 26.91 N in controls, 37.16 N with BPC-157, 37.41 N with TB-500 and 34.54 N with both, and only the TB-500 group differed significantly from controls (adjusted p = 0.0406). Of two tissue scores, the combination differed from controls on one (p = 0.040) and TB-500 on both. “No statistically significant differences were observed among treatment groups.”
The study was small and could have missed a real difference, so it does not show that combining adds nothing; it is the only test of “better together”, and it did not support it. Its peptides came from a seller of research peptides, unverified in the paper, which calls its TB-500 “synthetic thymosin beta-4 (TB-500)”. No other animal or cell study has given the two together.
Lab studies and how it is thought to work
No mechanism has been shown for the combination in people, in animals or in cells. For BPC-157 (animal studies and lab studies): new blood-vessel growth and effects on tendon cells, though the FDA notes that “the molecular targets for BPC-157 have not been identified”. For TB-500 (lab studies and animal studies): actin binding, cell movement and blood-vessel growth, mostly studied with thymosin beta-4 or a version of the fragment without the acetyl group; in the one cell test of TB-500 itself, it did not close wounds. That one acts locally and the other body-wide is theory: a surgeon’s page says of the idea, “this is purely theoretical at this point”.
On its own, neither ingredient has controlled evidence of benefit in people.
Dosing: what has been tested, what is used, and what the reasoning supports
This section reports and reasons; it recommends nothing. No study has compared one dose of the pair with another, so no dose can be called optimal.
Doses tested in people
Three published reports gave BPC-157 with TB-500 or with thymosin beta-4, and none was designed to find a dose. The 2021 chart review: BPC-157 “2-4 mg (1-2 doses)” (the FDA’s reading of the whole study) with “TB4” in an unstated amount, injected into the knee, in four adults. The 2026 dental case reports: BPC-157 1 mg and TB-500 10 mg under the lining of the mouth once a week for four weeks, with three other drugs, in three adults. The 2026 open-label pilot: BPC-157 0.8 mg and thymosin beta-4 1.65 mg (not TB-500), as separate injections under the skin once a week for 26 weeks, in five adults. No published human study has given BPC-157 and TB-500 together under the skin or into muscle, or as one mixed vial.
On its own, BPC-157 has been given to people by enema, into a knee, into the bladder wall and into a vein (BPC-157 review); TB-500 has no published human dose beyond the dental cases (TB-500 review).
Doses in common use
These amounts are in circulation: practice that no trial set, reported so that you can see where each number comes from. No published human study used any of them. (mcg and µg: micrograms.)
- Two products on two schedules, the pattern that recurs. A clinic’s dosage guide has BPC-157 “dosed at roughly 250–500 mcg per day by subcutaneous injection” and TB-500 at “a loading dose of about 2–2.5 mg twice weekly (≈4–5 mg/week) for 4–6 weeks, followed by a maintenance dose of about 2–2.5 mg once weekly”. The same guide adds: “These figures come from animal studies and clinical practice, not from large human efficacy trials.”
- One mixed vial, equal amounts, daily. A “research use only” seller’s page states “600–1000 mcg total blend once daily (provides 300–500 mcg of each peptide)”, injected under the skin. A telehealth prescribing service’s page states “0.6mg BPC-157 + 0.6mg TB-500 per injection”, “subcutaneous injection daily, Monday to Friday”.
- What forum users report taking. In the Reddit preprint, the median amount per injection was 366 µg of BPC-157 (middle half of users: 250 to 500) and 500 µg of TB-500 (350 to 2,000), and 76.3% injected under the skin. The authors: “no study has established an effective or safe human dose”.
Beside the doses studied: the only BPC-157 dose a study gave under the skin is the pilot’s 0.8 mg once a week, with thymosin beta-4, and the only TB-500 dose given to people is 10 mg once a week under the lining of the mouth, with other drugs, in three patients. The patterns also disagree with each other about TB-500 by a wide margin, and about whether the two are given on one schedule or two.
What the pharmacology supports, and what it doesn’t
- Amount. Convention. Nothing in the pharmacology sets one. A 2026 review of these peptides says “Validated dosing, pharmacokinetic, and long-term safety data are lacking”.
- Frequency, route and duration. Measured in animals: BPC-157’s half-life in rats and dogs was under 30 minutes; TB-500’s only blood-level data are from horses. Not measured: either peptide’s half-life in people, its blood levels after an injection, or anything about the two together. Inferred: the animal figures support no interval, so every schedule and cycle length for the pair is a convention; how long either peptide’s effects last in a person is unknown.
- One vial or two. Inferred. The mixed vials found hold equal amounts, so they cannot follow the two-product pattern; that shows the conventions are arbitrary, not which is better.
- Monitoring. Inferred. No test is specific to the pair. A prescriber would sensibly watch what each ingredient’s record points to: injection-site and allergic reactions, clotting tests in people on blood thinners, liver enzymes, glucose and triglycerides (BPC-157), and a history of cancer (both). TB-500 has no blood marker.
What nobody knows: whether the pair does anything one ingredient would not, how the two behave together in the body or in one solution, and what amount would be harmful.
What common protocols get wrong
- Thymosin beta-4’s record is cited for TB-500. One seller describes TB-500 as “well-tolerated in animal and early clinical studies, even at multi-milligram doses”. That is the protein’s record, not the fragment’s.
- A dose effect is claimed from a study whose abstract reports none. A seller’s page says a human case series “reported improved outcomes at higher combined doses (4 mg BPC + 6 mg TB-500 intra-articular) compared to lower doses.” The only such series, the 2021 knee review, names “thymosin-beta-4 (TB4)” and reports no comparison of doses in its abstract, and its four combination patients did no better than the twelve given BPC-157 alone. We could not confirm the “6 mg” figure.
- Repetition is taken for evidence. The numbers recur because pages copy one another: two sellers’ pages match, and a pharmacy chain’s guide reports the clinic’s figures.
A dose is the prescriber’s decision for one patient.
Safety, and who should be most cautious
In the published reports. No adverse events were reported in the four knee patients or the three dental patients. The pilot reported “No serious adverse events” over 26 weeks in its five treated patients, who had thymosin beta-4 and not TB-500; its table lists injection-site redness or itching in three, a firm lump there in two, lightheadedness in two, headache in one and one rise in the liver enzyme ALT that returned to normal. Twelve patients in three small unblinded reports cannot show safety.
Reports to the FDA. The FDA describes a 40-year-old woman who injected a “research purposes only” product containing BPC-157 and TB-500 twice a day. After a week she developed widespread darkening of the skin and gums, which returned when she restarted the product. The FDA judged the reactions “likely due to the drug product”, but “because the product contained two peptides it is not possible to assess a potential relationship between BPC-157 and the reported AEs” (AEs: adverse events). In the FDA’s public adverse-event data, read on November 19, 2026, 26 reports named BPC-157; three listed it and a thymosin product as suspect drugs, each flagged as serious, two alongside other suspect drugs. Such reports are unvalidated and do not show that a product caused an event.
What users report. In the Reddit preprint (all users, whichever peptide they took), “1,519 users (27.2%) reported at least one side effect”, most often fatigue, anxiety and loss of pleasure; 29 (0.5%) described a serious event, “most often a new or progressing cancer (6 users, 4 with basal cell carcinoma)”. The authors: “we cannot estimate their true frequency or establish causality”.
What is missing. Of each ingredient the FDA says that an injected peptide “may pose a significant risk for immunogenicity, potentially amplified by aggregation as well as potential peptide-related impurities” (immunogenicity: provoking an immune reaction). For the two together there is no toxicology study in any species, no interaction study, no immune-response data and no long-term data.
Who should be most cautious (theory). People with cancer, now or in the past, have the most reason for caution, on theory and not on data from people: each ingredient is described as promoting new blood-vessel growth in cell and animal studies, and tumors need new vessels to grow. Whether the two effects add is untested.
| Situation | What is known | Basis |
|---|---|---|
| Pregnancy, breastfeeding, children | No data on the pair | No published studies |
| Cancer, now or in the past | No data in people; a theoretical concern for both ingredients | Lab studies and animal studies of each; theory |
| Blood thinners or a bleeding disorder | BPC-157 changed clotting tests in rats and dogs; nothing is known in people | Animal studies (the FDA’s reading) |
Product quality
No published analysis of a mixed vial. We found none that tested how much of each peptide a mixed vial holds, how pure it is, or whether the two are stable together. The FDA says such peptides “can be extremely sensitive to product formulation, process, and environmental conditions”.
Recalls. The FDA’s records list two recalls of mixed vials labelled BPC-157 with “Thymosin Beta-4”: one begun by an outsourcing facility on July 30, 2025 for “Lack of Assurance of Sterility”, and one by a pharmacy on October 19, 2026 for “Lack of Processing Controls”. After inspecting the first firm, the FDA wrote that “drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions”.
Products sold online. The largest analysis we found, a 2026 preprint (not peer-reviewed), tested fourteen single peptides and no blend. In it TB-500 “had the highest identity failure rate at 10.0%, meaning that one in ten TB-500 samples did not contain the stated compound”. The authors say their dataset “is not a random or representative sample” and call their failure rates “a lower bound”.
“Research use only”. The product in the FDA’s case was “labeled for ‘research purposes only’”, and seller pages carry “For research use only. Not for human consumption.” beside a daily injection schedule.
What we make of it
This section is our reading of the evidence. It is a judgment, not a finding.
On the evidence, the Wolverine stack is unproven and experimental. The case for it rests on each ingredient separately, and that case is not empty: animal studies and lab studies of BPC-157, and of thymosin beta-4 more than of TB-500 itself, describe effects on blood-vessel growth and cell movement, so it is plausible that one or both could matter to an injured tendon. But plausibility for an ingredient is not evidence for a combination, and the one experiment that asked whether two are better than one, in rats, did not find that they are.
The claims outrun the evidence most at “better together”, “a standard protocol” and “safe”, and in treating TB-500 and thymosin beta-4 as one substance. The spinal cord injury pilot gave thymosin beta-4, not TB-500, and has the problems set out above; we read it as a lead to follow up, not a result to rely on.
For the pair to earn a place in care, a controlled comparison in people would have to show that it does more than each ingredient and more than placebo. For whom the pair might ever be considered, after what, with what monitoring and when to stop are clinical judgments, and they are our Medical Director’s to state.
Peptide care at Rock Creek Wellness
Our peptide care starts with lab tests and a visit with one of our providers. The provider decides whether any peptide suits you, and which one; you don’t choose from a menu. How that care works is set out on our peptide therapy page, along with the other reviews in this library. What Peptide Care costs is on the same page.
So that you can weigh this review knowing our interest: RCW’s providers prescribe some of the peptides reviewed in this library, and RCW earns money from that care.
What would change this review
- A controlled trial of the pair against each ingredient and against placebo. On November 19, 2026, ClinicalTrials.gov and the EU Clinical Trials Register listed none.
- Published testing of a mixed vial for content, purity and stability.
- A correction to the 2026 pilot’s paper, or its registration appearing in Cuba’s trial registry.
- Rulemaking: a final HHS policy, or FDA action on mixed products.
Common questions
Does the Wolverine stack work?
Nobody knows, because no randomized or blinded trial has tested it in people. Three small reports cover twelve patients, nine of them given thymosin beta-4, not TB-500; they describe improvement but cannot separate the peptides from natural recovery and other treatment. In the one animal study, the pair was no better than either peptide alone.
Is TB-500 the same as thymosin beta-4?
No. TB-500 is a seven-amino-acid fragment of thymosin beta-4, which has 43 amino acids, and the FDA says the two “are not the same substance”. Results for thymosin beta-4 do not transfer to TB-500.
Is the Wolverine stack safe?
That is not established. No serious adverse events were reported among the twelve patients in the published reports, only three of whom had TB-500 itself; the FDA describes one reaction to a mixed product. No safety study of the two together exists, in animals or in people.
Can a doctor prescribe it?
The FDA and HHS documents we read give no yes or no about prescribers: their conditions attach to the compounding and to the product, not to the writing of a prescription. Neither ingredient is FDA-approved, so any prescription would be for a compounded medicine, and a compounded injection combining the two is outside both HHS’s draft policy and the FDA’s Category 1 policy.
How much do people take, and how often?
No amount or schedule of the pair has been compared with another in people, so there is no evidence-based answer. Clinic, seller and telehealth pages state BPC-157 daily in the hundreds of micrograms, with TB-500 either daily in similar amounts or once or twice a week in milligrams: practice no trial set, in patterns that contradict one another. Neither peptide has a measured half-life in people, so nothing in the science fixes a schedule.
Sources
Show all 20 sourcesHide sources
- FDA Briefing Document: BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), Pharmacy Compounding Advisory Committee, July 23-24, 2026. US Food and Drug Administration, 2026.
- FDA Briefing Document: Evaluation of TB-500-related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate) for Inclusion on the 503A Bulk Drug Substances List. US Food and Drug Administration, 2026.
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. US Department of Health and Human Services, 2026.
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability, 91 FR 68526, FR Doc. 2026-22192). Federal Register, 2026.
- Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. US Food and Drug Administration, 2025.
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. US Food and Drug Administration, 2026.
- Warning Letter: GenoGenix LLC, MARCS-CMS 718739. US Food and Drug Administration, 2026.
- openFDA drug enforcement (recall) data. US Food and Drug Administration, 2026.
- openFDA drug adverse event (FAERS) data. US Food and Drug Administration, 2026.
- WADA 2026 Prohibited List; WADA 2027 Prohibited List. World Anti-Doping Agency, 2025 and 2026.
- Adjunctive Weekly Subcutaneous Thymosin β4 and BPC-157 With Intensive Rehabilitation in Subacute AIS-B Thoracic Spinal Cord Injury: A 6-Month Open-Label Controlled Pilot Study. American Journal of Medical and Clinical Research & Reviews, 2026.
- Registro Público Cubano de Ensayos Clínicos (RPCEC). Registro Público Cubano de Ensayos Clínicos, read 2026.
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine, 2021.
- Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Frontiers in Oral Health, 2026.
- Real-World Use, Dosing, and Reported Side Effects of BPC-157 and TB-500 for Musculoskeletal Injury: An Analysis of Online Communities. medRxiv (not peer-reviewed), 2026.
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Diseases and Related Surgery, 2026.
- Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. Journal of the American Academy of Orthopaedic Surgeons, 2026.
- Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance. Preprints.org (not peer-reviewed), 2026.
- ClinicalTrials.gov API v2. US National Library of Medicine, searched 2026.
- EU Clinical Trials Register. European Medicines Agency, searched 2026.
